NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
2 min read
0
In this article:

For the quarter ended December 2023, NeoGenomics (NEO) reported revenue of $155.55 million, up 12.1% over the same period last year. EPS came in at $0.03, compared to -$0.06 in the year-ago quarter.

The reported revenue represents a surprise of +1.73% over the Zacks Consensus Estimate of $152.9 million. With the consensus EPS estimate being -$0.01, the EPS surprise was +400.00%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how NeoGenomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Clinical - Number of tests performed: 294,850 compared to the 295,996 average estimate based on three analysts.

  • Clinical - Average revenue/test: $0.44 versus the three-analyst average estimate of $0.42.

  • Revenue- Advanced Diagnostics: $25.49 million compared to the $24.81 million average estimate based on four analysts. The reported number represents a change of -16.5% year over year.

  • Revenue- Clinical Services: $130.06 million versus the four-analyst average estimate of $126.02 million. The reported number represents a year-over-year change of +20.2%.

  • Gross Profit- Advanced Diagnostics: $11.56 million versus the three-analyst average estimate of $9.55 million.

  • Gross Profit- Clinical Services: $56.03 million compared to the $57.80 million average estimate based on three analysts.

View all Key Company Metrics for NeoGenomics here>>>

Shares of NeoGenomics have returned -10.3% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NeoGenomics, Inc. (NEO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement

Recommended Stories